Author

A. Hata

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:metabolomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Lopez· 1 shared A. Prabhakar· 1 shared A. Regev· 1 shared B. B. Graham· 1 shared B. N. Kharbikar· 1 shared B. Neel· 1 shared C. M. Dowling· 1 shared C. M. Rudin· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Lopez

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Reversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response

A. Prabhakar, R. Kumar, M. Wadhwa, P. Ghatpande, J. Zhang, Z. Zhao, C. O. Lizama, B. N. Kharbikar, S. Graf, C. M. Treacy, N. W. Morrell, B. B. Graham, G. Lagna, A. Hata

This study shows that inhibiting the integrated stress response (ISR) or PKR reduces vascular remodeling in PVOD models, suggesting potential therapeutic strategies.

bioRxiv · Nov 27, 2023 · PreprintCell Biology

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer

J. Deng, D. H. Peng, D. Fenyo, Y. Hao, A. Lopez, D. Levin, M. Meynardie, M. Quinteros, M. Ranieri, S. Sahu, S. Lau, E. Shum, V. Velcheti, S. R. Punekar, N. Rekhtman, , K.-K. Wong

The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.

bioRxiv · Apr 18, 2023 · PreprintCancer Biology

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programs

Y. Oren, M. Tsabar, H. F. Cabanos, M. S. Cuoco, E. Zaganjor, P. I. Thakore, M. Tabaka, C. P. Fulco, S. A. Hurvitz, D. J. Slamon, G. Lahav, A. Hata, J. S. Brugge, A. Regev

The paper identifies cycling cancer persisters with distinct transcriptional and metabolic programs using a new tracing system and shows that targeting oxidative stress or metabolic reprogramming reduces their fraction.

bioRxiv · Jun 5, 2020Cancer Biology